par Desmedt, Christine
;Di Leo, Angelo
;de Azambuja, Evandro
;Larsimont, Denis
;Haibe-Kains, Benjamin
;Selleslags, Jean;Delaloge, Suzette;Duhem, Caroline;Kains, Jean-Pierre;Carly, Birgit;Maerevoet, Marie
;Vindevoghel, Anita;Rouas, Ghizlane;Lallemand, Françoise;Durbecq, Virginie
;Cardoso, Fatima
;Salgado, Roberto;Kraft Rovere, Rodrigo
;Bontempi, Gianluca
;Michiels, Stefan
;Buyse, Marc;Nogaret, Jean-Marie
;Qi, Yuan;Symmans, Fraser;Pusztai, Lajos;D'Hondt, Veronique
;Piccart-Gebhart, Martine
;Sotiriou, Christos 
Référence Journal of clinical oncology, 29, 12, page (1578-1586)
Publication Publié, 2011-04















Référence Journal of clinical oncology, 29, 12, page (1578-1586)
Publication Publié, 2011-04
Article révisé par les pairs
Résumé : | Validated biomarkers predictive of response/resistance to anthracyclines in breast cancer are currently lacking. The neoadjuvant Trial of Principle (TOP) study, in which patients with estrogen receptor (ER) -negative tumors were treated with anthracycline (epirubicin) monotherapy, was specifically designed to evaluate the predictive value of topoisomerase II-α (TOP2A) and develop a gene expression signature to identify those patients who do not benefit from anthracyclines. |